All in all, our in vitro and in vivo data support phenformin as a promising candidate for ErbB2+ breast cancer treatment and provides the foundation for future studies on the anti-cancer mechanisms of biguanide drugs. This evidence concerns the gene ERBB2 and breast carcinoma.